Safi Biotherapeutics Solidifies Leading Position in Red Blood Cell Biomanufacturing with Acquisition of EryPharm Assets

Safi Biotherapeutics (“Safi”), a leader in the field of allogeneic biomanufacture of blood cells, proudly announces the successful completion of an agreement to acquire all assets of EryPharm, a prominent player in the development of advanced red blood cell therapeutics. This strategic move marks a significant step forward for Safi, positioning the company at the forefront of industrial scale biomanufactured red blood cell production, an innovative alternative to traditional donor blood products. The acquisition brings together the cutting-edge proprietary technologies of both Safi and the French biotechnology company EryPharm, creating a powerful synergy that is poised to revolutionize the biomanufacturing landscape.

Read the full article: Safi Biotherapeutics Solidifies Leading Position in Red Blood Cell Biomanufacturing with Acquisition of EryPharm Assets //

Source: https://www.einpresswire.com/article/679101212/safi-biotherapeutics-solidifies-leading-position-in-red-blood-cell-biomanufacturing-with-acquisition-of-erypharm-assets

Leave a Comment

Your email address will not be published.

Scroll to Top